

**Sun Pharmaceutical Industries Limited**  
SUN HOUSE, CTS No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai 400063, India  
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343  
Website: [www.sunpharma.com](http://www.sunpharma.com)  
Email: [secretarial@sunpharma.com](mailto:secretarial@sunpharma.com)  
CIN: L24230GJ1993PLC019050



9 September 2025

**National Stock Exchange of India Limited**  
Scrip Symbol: SUNPHARMA

**BSE Limited**  
Scrip Code: 524715

### **Update on US FDA Inspection at Sun Pharma Halol Facility**

Further to our intimation dated [14 June 2025](#) regarding the subject matter, in which we had informed that the U.S. Food and Drug Administration (FDA) conducted an inspection at the Company's Halol Facility from 2 June to 13 June 2025, the FDA has now classified the facility as "Official Action Indicated" (OAI). This means the FDA considers the facility to be not fully compliant with regard to certain current good manufacturing practices (CGMP).

The Halol facility is under Import Alert, resulting in the refusal of shipments from the facility into the US, barring certain exemptions due to drug shortage, until the facility becomes fully compliant with FDA and CGMP standards.

Sun Pharma remains committed to working with the FDA and maintaining CGMP standards at all of its facilities to provide high-quality medicines to patients globally.

**For Sun Pharmaceutical Industries Limited**

(Anoop Deshpande)  
**Company Secretary and Compliance Officer**  
ICSI Membership No.: A23983